EXHIBIT 31.2


                          CERTIFICATION OF XIAN FEN GUO
            PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

In connection  with the  accompanying  Quarterly  Report on Form 10-QSB of Axiom
Pharmaceuticals,  Inc.  for the period  ended June 30,  2003,  as filed with the
Securities and Exchange  Commission on the date hereof, the undersigned,  in the
capacity and date indicated below, hereby certifies that:

1.   I  have   reviewed   this   quarterly   report  on  Form  10-QSB  of  Axiom
     Pharmaceuticals, Inc.;

2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     annual report;

4.   The  registrant's  other  certifying  officers  and I are  responsible  for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:

   (a) designed  such  disclosure  controls  and  procedures,   or  caused  such
       disclosure  controls and procedures to be designed under our supervision,
       to ensure that material information relating to the registrant, including
       its consolidated subsidiaries, is made known to us by others within those
       entities,  particularly  during the period in which this quarterly report
       is being prepared;

   (b) evaluated the effectiveness of the registrant's  disclosure  controls and
       procedures  and  presented  in this  report  our  conclusions  about  the
       effectiveness of the disclosure controls and procedures, as of the end of
       the period covered by this report based on such evaluation; and

   (c) disclosed in this report any change in the registrant's  internal control
       over  financial  reporting  that occurred  during the  registrant's  most
       recent fiscal quarter (the registrant's fourth fiscal quarter in the case
       of an annual report) that has materially affected or is reasonably likely
       to materially  affect,  the registrant's  internal control over financial
       reporting; and

5.   The registrant's other certifying  officers and I have disclosed,  based on
     our most recent evaluation of internal control over financial reporting, to
     the registrant's  auditors and the audit committee of registrant's board of
     directors (or persons performing the equivalent functions):


<PAGE>

   (a) all  significant  deficiencies  and material  weaknesses in the design or
       operation  of  internal  control  over  financial   reporting  which  are
       reasonably likely to adversely affect the registrant's ability to record,
       process, summarize and report financial information; and

   (b) any fraud,  whether or not material,  that  involves  management or other
       employees  who  have a  significant  role  in the  registrant's  internal
       controls; and




By:      /s/ Xian Fen Guo                                Date: August 13, 2003
         ------------------                                    ---------------
         Xian Fen Guo,
         Chief Financial Officer